Ishikane T
Department of Psychiatry and Neurology, Hokkaido University School of Medicine, Sapporo, Japan.
Hokkaido Igaku Zasshi. 1998 Sep;73(5):441-9.
We examined the modulatory effect of serotonergic activities on haloperidol-induced up-regulation of dopamine D2 receptors in rat striatum. Chronic treatment with haloperidol (0.1, 0.5 mg/kg, i.p., 3 weeks) increased the number of dopamine D2 receptors, while no increase was observed with atypical antipsychotic drugs clozapine (10 mg/kg) and ORG 5222 (0.25 mg/kg). Chronic treatment with MK 212, a serotonin (5-HT)2A/2C receptor agonist (2.5 mg/kg), or with citalopram, a 5-HT reuptake inhibitor (10 mg/kg), potentiated the haloperidol (0.1 mg/kg)-induced up-regulation of dopamine D2 receptor, while that with (+/-)-8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a 5-HT1A receptor agonist (0.1 mg/kg), had no influence on the dopamine D2 receptor up-regulation. Co-administration of ritanserin (1 mg/kg), a 5-HT2A/2C receptor antagonist, with a low dose of haloperidol (0.1 mg/kg), but not with a high dose of the agent (0.5 mg/kg), attenuated the dopamine D2 receptor up-regulation. Drug occupation of 5-HT2A and dopamine D2 receptors in vivo examined with use of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was 69.8% and 45.1%, respectively, after the acute administration of haloperidol (0.1 mg/kg) plus ritanserin (1 mg/kg). This profile that 5-HT2A receptors were highly occupied compared with dopamine D2 receptors was similar to that of clozapine or ORG 5222. These results suggest that potent 5-HT2A receptor antagonism versus weak dopamine D2 receptor blockade may be involved in the absence of up-regulation of dopamine D2 receptors after chronic treatment with clozapine or ORG 5222.
我们研究了血清素能活性对氟哌啶醇诱导的大鼠纹状体中多巴胺D2受体上调的调节作用。长期给予氟哌啶醇(0.1、0.5毫克/千克,腹腔注射,3周)可增加多巴胺D2受体的数量,而非典型抗精神病药物氯氮平(10毫克/千克)和ORG 5222(0.25毫克/千克)则未观察到增加。长期给予5-羟色胺(5-HT)2A/2C受体激动剂MK 212(2.5毫克/千克)或5-羟色胺再摄取抑制剂西酞普兰(10毫克/千克)可增强氟哌啶醇(0.1毫克/千克)诱导的多巴胺D2受体上调,而5-HT1A受体激动剂(+/-)-8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)(0.1毫克/千克)对多巴胺D2受体上调没有影响。5-HT2A/2C受体拮抗剂利坦色林(1毫克/千克)与低剂量氟哌啶醇(0.1毫克/千克)联合给药可减弱多巴胺D2受体上调,但与高剂量氟哌啶醇(0.5毫克/千克)联合给药则无此作用。急性给予氟哌啶醇(0.1毫克/千克)加 利坦色林(1毫克/千克)后,用N-乙氧羰基-2-乙氧基-1,2-二氢喹啉(EEDQ)检测体内5-HT2A和多巴胺D2受体的药物占有率分别为69.8%和45.1%。与多巴胺D2受体相比,5-HT2A受体被高度占据的这种情况与氯氮平或ORG 5222相似。这些结果表明,强效的5-HT2A受体拮抗作用与弱的多巴胺D2受体阻断作用可能与氯氮平或ORG 5222长期治疗后多巴胺D2受体未上调有关。